Purdue Pharma to Close as Part of Opioid Crisis Lawsuit Settlement

The closure of Purdue Pharma marks a significant, albeit overdue, step in addressing the devastating opioid crisis that has ravaged communities across the United States. For years, Purdue Pharma, under the ownership of the Sackler family, aggressively marketed OxyContin, downplaying its addictive potential and fueling an epidemic that has claimed countless lives and shattered families.

“

Knoa Pharma will be owned exclusively by the Knoa Fund, a non-profit organization, and will manufacture medicines, including opioids, safely and responsibly to meet public health needs.

This bankruptcy agreement, brokered by a coalition of 54 attorneys general led by New York, finally brings a measure of accountability. The establishment of Knoa Pharma, a public benefit corporation, signals a shift towards prioritizing public health over profit. While it will continue to manufacture medications, including opioids, it will operate under strict independent supervision, with political lobbying and direct-to-consumer advertising of opioids prohibited.

The financial repercussions for the Sackler family are substantial, with significant payments mandated over the next several years. More importantly, their direct involvement in the opioid market in the U.S. is now prohibited. The settlement funds are earmarked for state, local, and tribal governments, as well as victims and treatment programs, offering a glimmer of hope for recovery and prevention efforts.

“

who drove the opioid crisis through their ownership and operation of Purdue

This case underscores the critical role of state prosecutors in holding powerful corporations accountable. While Western media often focuses on the human tragedy, from a U.S. perspective, this is also a story of legal and regulatory battles, where persistent advocacy has finally yielded a form of justice, even if it cannot undo the immense harm caused.

“

one million girls would kill for this job